You can download the 2016 BTEC meeting report
The Brain Tumor Epidemiology Consortium (BTEC) announces the availability of two Junior Investigator Awards to its 2017 meeting. The meeting title is
Brain tumor epidemiology in the era of precision medicine
Banff Conference Center- Alberta – June 27-29, 2017
The Brain Tumor Epidemiology Consortium held its annual meeting at Mayo Clinic in Rochester, MN, June 2-4, 2015 and hosted by Robert Jenkins and Brian Patrick O’Neill. This year’s meeting theme “Evolving Evidence on Tumor and Germline Genetic Classification of Gliomas: Implications for Etiology and Survival Studies” included presentations that emphasized new findings in the impact on clinical outcome of new tumor genetic classifications, methodological practice of population studies, and intratumoral genetic and biological complexities of tumors.
Brain tumor oncologists and researchers have long defined gliomas by their physical appearance under a microscope. Along with location and size, standard pathological definitions include glioma grade (low grade - II, III, and high grade, or glioblastoma IV) and morphology (astrocytoma, oligodendroglioma, and mixed). These morphological characteristics play a large role in guiding treatment decisions: generally lower grade tumors are treated less aggressively.
Find the CBTRUS reports in the publications section
Telomeres are DNA-based "caps" that exist on the ends of chromosomes. These "caps" are composed of a hexanucleotide unit "TTAGGG" which is repeated tens to thousands of times at the end of the chromosome, and help stabilize the end by attracting specific proteins. When cells are young, telomeres are long; this is also true of telomeres in germ cells and embryonic cells. As cells age, telomeres progressively shorten until they degrade completely; this degradation process signals the end of the life for a particular cell as it then becomes genetically unstable and dies.